Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces four abstract presentations at the AUA 2025, highlighting the benefits of Blue Light Cystoscopy (BLC®), notably its impact on management ...

Three abstracts were presented from Photocure's U.S. Blue Light Cystoscopy with Cysview Registry, a large multicenter bladder cancer patient registry of real-world data, established by Photocure ...

Among patients with non-muscle-invasive bladder cancer (NMIBC), neoadjuvant treatment with mitomycin C prior to transurethral ...

With an FDA review underway, Johnson & Johnson is aiming to “fundamentally change” how bladder cancer is treated. | With an ...

According to a market report by Lucintel, the future of the global bladder cancer diagnostic market looks promising with ...

The positive predictive value (PPV) for Bladder EpiCheck was 67.4%, with a negative predictive value (NPV) for both overall and HG disease of 99.6%. WLC demonstrated a PPV of 74%, an NPV of 96.3%, and ...

AUA annual meeting featured the 4 th annual IBCG Bladder Cancer Forum evaluating common problems and controversies in bladder cancer, moderated by Dr. Bernard Bochner, with a debate between Drs. Sia ...

Cystoscopy is when your doctor uses a small tube with a light to see the inside of your bladder and urethra. They may also use fluorescent dye to better see the cancer. This is the most commonly ...

ALA-guided fluorescence cystoscopy is already widely used, and in March 2005 HAL was approved in Europe for the diagnosis of bladder cancer. The approval process continues in the US. Technical ...